1002 related articles for article (PubMed ID: 27343741)
1. Canadian Cardiovascular Society Guidelines for Evaluation and Management of Cardiovascular Complications of Cancer Therapy.
Virani SA; Dent S; Brezden-Masley C; Clarke B; Davis MK; Jassal DS; Johnson C; Lemieux J; Paterson I; Sebag IA; Simmons C; Sulpher J; Thain K; Thavendiranathan P; Wentzell JR; Wurtele N; Côté MA; Fine NM; Haddad H; Hayley BD; Hopkins S; Joy AA; Rayson D; Stadnick E; Straatman L
Can J Cardiol; 2016 Jul; 32(7):831-41. PubMed ID: 27343741
[TBL] [Abstract][Full Text] [Related]
2. Cancer Therapy-Related Cardiac Dysfunction: Unresolved Issues.
Marwick TH
Can J Cardiol; 2016 Jul; 32(7):842-6. PubMed ID: 27343742
[TBL] [Abstract][Full Text] [Related]
3. Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management.
Curigliano G; Cardinale D; Dent S; Criscitiello C; Aseyev O; Lenihan D; Cipolla CM
CA Cancer J Clin; 2016 Jul; 66(4):309-25. PubMed ID: 26919165
[TBL] [Abstract][Full Text] [Related]
4. Identifying cancer patients at risk for cardiotoxicity.
Salvatici M; Sandri MT
Future Oncol; 2015; 11(14):2077-91. PubMed ID: 26198838
[TBL] [Abstract][Full Text] [Related]
5. Left Ventricular Dysfunction and Chemotherapeutic Agents.
Clasen SC; Wald JW
Curr Cardiol Rep; 2018 Mar; 20(4):20. PubMed ID: 29520629
[TBL] [Abstract][Full Text] [Related]
6. Neurohormonal Blockade and Circulating Cardiovascular Biomarkers During Anthracycline Therapy in Breast Cancer Patients: Results From the PRADA (Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy) Study.
Gulati G; Heck SL; Røsjø H; Ree AH; Hoffmann P; Hagve TA; Norseth J; Gravdehaug B; Steine K; Geisler J; Omland T
J Am Heart Assoc; 2017 Nov; 6(11):. PubMed ID: 29118031
[TBL] [Abstract][Full Text] [Related]
7. Cardio-oncology: a multidisciplinary approach for detection, prevention and management of cardiac dysfunction in cancer patients.
Tajiri K; Aonuma K; Sekine I
Jpn J Clin Oncol; 2017 Aug; 47(8):678-682. PubMed ID: 28505345
[TBL] [Abstract][Full Text] [Related]
8. Organization and implementation of a cardio-oncology program.
Fiuza M; Ribeiro L; Magalhães A; Sousa AR; Nobre Menezes M; Jorge M; Costa L; Pinto FJ
Rev Port Cardiol; 2016 Sep; 35(9):485-94. PubMed ID: 27503589
[TBL] [Abstract][Full Text] [Related]
9. Cardiotoxic effects of anthracycline-based therapy: what is the evidence and what are the potential harms?
Levis BE; Binkley PF; Shapiro CL
Lancet Oncol; 2017 Aug; 18(8):e445-e456. PubMed ID: 28759384
[TBL] [Abstract][Full Text] [Related]
10. Cardio-oncology, the myth of Sisyphus, and cardiovascular disease in breast cancer survivors.
Mavrogeni SI; Sfendouraki E; Markousis-Mavrogenis G; Rigopoulos A; Noutsias M; Kolovou G; Angeli C; Tousoulis D
Heart Fail Rev; 2019 Nov; 24(6):977-987. PubMed ID: 31134427
[TBL] [Abstract][Full Text] [Related]
11. Cardio-oncology in Austria: cardiotoxicity and surveillance of anti-cancer therapies : Position paper of the Heart Failure Working Group of the Austrian Society of Cardiology.
Bergler-Klein J; Rainer PP; Wallner M; Zaruba MM; Dörler J; Böhmer A; Buchacher T; Frey M; Adlbrecht C; Bartsch R; Gyöngyösi M; Fürst UM
Wien Klin Wochenschr; 2022 Sep; 134(17-18):654-674. PubMed ID: 35507087
[TBL] [Abstract][Full Text] [Related]
12. Cardio-oncology Part II: the monitoring, prevention, detection and treatment of chemotherapeutic cardiac toxicity.
O'Hare M; Murphy K; Mookadam F; Sharma A; Lee H
Expert Rev Cardiovasc Ther; 2015 May; 13(5):519-27. PubMed ID: 25864865
[TBL] [Abstract][Full Text] [Related]
13. Cardiac Outcomes in Survivors of Pediatric and Adult Cancers.
Nathan PC; Amir E; Abdel-Qadir H
Can J Cardiol; 2016 Jul; 32(7):871-80. PubMed ID: 27179545
[TBL] [Abstract][Full Text] [Related]
14. Echocardiography and Alternative Cardiac Imaging Strategies for Long-Term Cardiotoxicity Surveillance of Cancer Survivors Treated with Chemotherapy and/or Radiation Exposure.
Garg V; Vorobiof G
Curr Oncol Rep; 2016 Aug; 18(8):52. PubMed ID: 27461436
[TBL] [Abstract][Full Text] [Related]
15. Protecting the heart in cancer therapy.
Finet JE; Tang WHW
F1000Res; 2018; 7():. PubMed ID: 30345014
[TBL] [Abstract][Full Text] [Related]
16. [Cardiotoxicity of anticancer therapies. Towards the implementation of cardio-oncology units].
Hameau R; Gabrielli L; Garrido M; Guzmán AM; Retamal I; Vacarezza MJ; Greig D; Ocqueteau M; Sánchez C; Pizarro M; Corvalán A; Lavandero S; Castro PF; Martínez G
Rev Med Chil; 2018 Jan; 146(1):68-77. PubMed ID: 29806680
[TBL] [Abstract][Full Text] [Related]
17. Cancer survivorship: cardiotoxic therapy in the adult cancer patient; cardiac outcomes with recommendations for patient management.
Steingart RM; Yadav N; Manrique C; Carver JR; Liu J
Semin Oncol; 2013 Dec; 40(6):690-708. PubMed ID: 24331191
[TBL] [Abstract][Full Text] [Related]
18. Cardio-oncology: the role of advanced echocardiography in cancer patients.
Venneri L; Zoppellaro G; Khattar RS
Expert Rev Cardiovasc Ther; 2018 Apr; 16(4):249-258. PubMed ID: 29457984
[TBL] [Abstract][Full Text] [Related]
19. [MODERN ASPECTS OF DIAGNOSIS AND TREATMENT OF HEART FAILURE, AS A MANIFESTATION OF ANTHRACYCLINE CARDIOTOXICITY (REVIEW)].
Saganelidze K; Kavtaradze N
Georgian Med News; 2018 May; (278):87-93. PubMed ID: 29905551
[TBL] [Abstract][Full Text] [Related]
20. SEOM clinical guidelines on cardiovascular toxicity (2018).
Virizuela JA; García AM; de Las Peñas R; Santaballa A; Andrés R; Beato C; de la Cruz S; Gavilá J; González-Santiago S; Fernández TL
Clin Transl Oncol; 2019 Jan; 21(1):94-105. PubMed ID: 30627982
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
